• Electrical Stimulation Enhances Nanoparticle Uptake in Cance

  2026-06-10

  This article reviews how alternating current (AC) electrical stimulation substantially increases the endocytosis of magnetic nanoparticles by diverse cancer cell types, as demonstrated by Wang et al. The findings highlight new, broadly applicable strategies for improving nanoparticle-based diagnostics and therapies through physical modulation of cell uptake pathways.

• Tetrazolium (chloride): Reliable Indicator for Mitochondrial

  2026-06-10

  Tetrazolium (chloride), also known as Tetrazolium Red or TTC, is a robust redox indicator for mitochondrial function and cell viability assays. Its enzymatic reduction by mitochondrial dehydrogenases provides a quantitative readout of tissue viability, particularly in ischemic injury research.

• Microplastics/Nanoplastics Drive Pulmonary Fibrosis via FXR-

  2026-06-09

  This study elucidates how inhaled microplastics (MPs) and nanoplastics (NPs), particularly polystyrene nanoplastics, exacerbate pulmonary fibrosis through dysregulation of the FXR-YAP1 signaling axis. The findings provide mechanistic insights into polymer- and size-specific pulmonary toxicity, with implications for environmental health risk assessment.

• HDAC Inhibitors Suppress NUT Function in NUT Carcinoma Cells

  2026-06-09

  Shiota et al. conducted a high-throughput chemical screen revealing that diverse histone deacetylase (HDAC) inhibitors can repress oncogenic NUT function in NUT carcinoma. Their findings uncover a mechanistic basis for HDAC inhibition as a potential therapeutic strategy, highlighting new avenues for treating this aggressive cancer.

• IGFBP2-THBS1 Axis Mediates GH-Induced Bone Growth in ISS Chi

  2026-06-08

  This study uncovers a novel IGFBP2-THBS1 regulatory axis underlying the action of recombinant human growth hormone (GH) in promoting bone growth in idiopathic short stature (ISS) children. By demonstrating that GH therapy activates the IGF-1 pathway via IGFBP2-mediated inhibition of THBS1, the research clarifies molecular mechanisms and highlights new potential targets for optimizing ISS treatment.

• Tetracycline: Broad-Spectrum Polyketide Antibiotic for Resea

  2026-06-08

  Tetracycline is a well-characterized broad-spectrum polyketide antibiotic that inhibits bacterial protein synthesis by targeting ribosomal subunits. Its molecular properties and storage requirements make it a mainstay in microbiological research, including as an antibiotic selection marker and ribosomal function probe.

• Ceramides Drive Autophagy and Viral Replication in Fish Noda

  2026-06-07

  This study applies global lipidomics to demonstrate that ceramide accumulation is a pro-viral factor during red-spotted grouper nervous necrosis virus (RGNNV) infection. By dissecting ceramide metabolic pathways and their link to autophagy, the research uncovers new molecular targets for antiviral strategies in aquaculture.

• ETS1 Regulates Mitophagy via SENP2/HSPA8/FUNDC1 in BPD Model

  2026-06-06

  This study demonstrates that ETS1 acts as a transcriptional regulator to inhibit mitochondrial damage-induced autophagy through the SENP2/HSPA8/FUNDC1 axis, thereby protecting against bronchopulmonary dysplasia (BPD). These findings provide new mechanistic insight into mitophagy regulation in lung injury and highlight potential molecular targets for BPD intervention.

• Anti-b Attenuates Hyperlipidaemia via mTOR/PPARγ and SREBP1

  2026-06-05

  This study identifies Anti-b as a novel small molecule that lowers blood lipid and hepatic fat accumulation in rodent and cell models of hyperlipidaemia. The research demonstrates that Anti-b achieves these effects by directly binding to mTOR, leading to suppression of downstream PPARγ and SREBP1 signaling, highlighting a mechanistically distinct strategy for metabolic disease intervention.

• BMS 309403: Unveiling FABP4 Inhibition in Atherosclerosis Me

  2026-06-05

  Explore how BMS 309403, a potent FABP4 inhibitor, enables advanced mechanistic dissection of lipid metabolism and inflammation in atherosclerosis. This in-depth analysis uniquely connects molecular pathways with practical assay design, offering fresh insights for metabolic disease research.

• Sulfo-Cy5 Carboxylic Acid: Precision Fluorescent Dye for Lif

  2026-06-04

  Sulfo-Cy5 carboxylic acid delivers unmatched hydrophilicity and minimized fluorescence quenching, making it a top-tier fluorescent dye for life sciences. Its robust optical performance and simplified aqueous labeling protocols empower sensitive protein and peptide assays—especially where organic solvents are undesirable.

• Berberine Hydrochloride in Gut–Bone Axis and Metabolic Resea

  2026-06-04

  Berberine hydrochloride offers researchers a unique tool to dissect the gut–bone axis and metabolic regulation, going beyond its classic antidiarrheal and antibacterial roles. Recent studies reveal its ability to induce intestinal tuft cell expansion, opening new doors for postmenopausal osteoporosis and osteoimmune investigation. This guide details experimental workflows, troubleshooting, and advanced applications to maximize reproducibility with APExBIO’s high-purity reagent.

• Metformin-Induced EDH Vasorelaxation in Colitis: Mechanisms

  2026-06-03

  This study elucidates how metformin induces vasorelaxation of mesenteric arterioles via endothelium-dependent hyperpolarization (EDH), offering protection against colitis-associated microvascular dysfunction. The mechanistic insights highlight the therapeutic potential of metformin for ulcerative colitis, especially in patients with type 2 diabetes mellitus.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-06-03

  DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe enables high-contrast plasma membrane visualization in live and fixed cells, addressing the need for robust and reproducible membrane-specific labeling in neuronal tracing and cell migration assays. It is not suitable for water-based staining or for targeting organelles beyond the plasma membrane, and correct protocol adherence is essential to avoid dye mislocalization and signal loss.

• MOG (35-55): Advancing Autoimmune Encephalomyelitis Research

  2026-06-02

  The MOG (35-55) myelin oligodendrocyte glycoprotein peptide is the gold-standard tool for inducing experimental autoimmune encephalomyelitis, enabling robust modeling of multiple sclerosis pathogenesis and therapeutic responses. This article delivers actionable protocols, troubleshooting insights, and strategic innovations—bridging bench research with translational breakthroughs.

450 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page